Your session is about to expire
← Back to Search
BI 690517 mild hepatic impairment (Child-Pugh A) for Liver Disease
Study Summary
This trial tests how mild & moderate liver disease affects drug safety, how it's absorbed & how well it's tolerated.
- Liver Disease
- Healthy Subjects
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
How much of a risk does BI 690517 mild hepatic impairment (Child-Pugh A) pose to individuals?
"With limited clinical evidence to support safety and efficacy, BI 690517 received a score of 1 for mild hepatic impairment (Child-Pugh A)."
How numerous are the participants of this research endeavor?
"Indeed, the information publicly available from clinicaltrials.gov affirms that recruitment for this study is ongoing. It was originally advertised on February 21st 2023 and has been recently modified on February 27th 2023, with a goal of enrolling 32 subjects between 2 medical centers."
Is there still capacity to enroll individuals in this experiment?
"The clinical trial is presently searching for participants, and its most recent iteration was posted on February 27th 2023. Furthermore, the original posting dates back to February 21st of that same year."
Share this study with friends
Copy Link
Messenger